Caribou Biosciences, Inc. Common Stock
CRBUCaribou Biosciences, Inc. is a biotechnology company focused on developing gene-editing technologies using CRISPR-Cas3 and other CRISPR-based tools. Founded in 2011, it specializes in precision gene editing for applications in agriculture, human therapeutics, and industrial biotechnology. The company's platform aims to enable more efficient, accurate, and versatile genetic modifications to address various biological challenges.
Company News
Caribou Biosciences announced positive clinical data for its CRISPR-based CAR-T cell therapies. Vispa-cel demonstrated an 82% overall response rate and 67% complete response rate in second-line large B cell lymphoma patients with a 17.1-month median progression-free survival. CB-011 showed an 83% complete response rate and 91% MRD negativity in h...
Caribou Biosciences reported positive clinical data for CB-011, its off-the-shelf BCMA-targeted CAR-T cell therapy for relapsed/refractory multiple myeloma. In 12 BCMA-naïve patients at the recommended dose, CB-011 achieved 83% complete response rate, 91% MRD negativity, and 50% of patients remained in complete response at 15 months with a manag...
The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target...
Caribou Biosciences reported promising first clinical data for CB-011, an off-the-shelf allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma, with 92% overall response rate and a manageable safety profile.
CRISPR therapies are showing significant potential with over 25 key companies developing 30+ pipeline therapies targeting genetic disorders, with promising clinical trials across various disease areas.
